Raphaël Rousseau

Dr. Rousseau has more than 25 years of experience in oncology drug development and leadership, with extensive experience developing therapeutic antibodies, cancer vaccines, engineered T cell therapies, and small molecule inhibitors. Prior to Pheast, he served as CMO at Gritstone Bio, Neogene Therapeutics, and Day One Biopharmaceuticals, where he was instrumental in building clinical teams and executing global development strategies from first-in-human to phase 3 registrational clinical trials in adult and pediatric oncology indications. Previously, Dr. Rousseau had increased responsibilities and ultimately served as the global franchise head of pediatrics at Genentech and Roche. Before his roles in pharma and biotech, Dr. Rousseau was a tenured professor of medical and pediatric oncology at the Université Claude Bernard and Léon Bérard Comprehensive Cancer Center in Lyon, France, where he founded and led a European academic consortium evaluating CD19 CAR T cells for children with high-risk leukemias. He completed his fellowship at the Texas Children’s Cancer Center and the Center for Cell and Gene Therapy in Houston, Texas. Dr. Rousseau holds a Ph.D. in Therapeutic Biotechnologies from Université Denis Diderot and an M.D. from Université René Descartes in Paris, France.